Pharma/Biotech Update: FDA approves Novo Nordisk’s Tretten
December 26, 2013; Posted by: WeBleed staff
Food and Drug Administration (FDA) approves Tretten for the treatment of adults and children with congenital Factor XIII deficiency.
Those who have been diagnosed with factor VIII deficiency, also known as hemophilia A, will soon have another option for their treatment, compliments of Novo Nordisk.
Results showed monthly doses of Novo Nordisk’s Tretten reduced bleeding in 90% of patients.
Karen Midthun, MD, director of the FDA’s Center for Biologics Evaluation and Research, said in a press release via Healio, “The approval of this product provides another therapeutic option for the prevention of bleeding in patients with Factor XIII A-subunit deficiency. Without treatment, people with this rare condition are at risk for serious and life-threatening bleeding.”
WeBleed will continue to keep you updated as more information becomes available concerning the production of Tretten.
webleed.org – your source for bleeding news!
Photo Credit: Novo Nordisk
